Logistic regression models showing the odds of neonatal death in France compared with Ontario
| Variable | No. of neonatal deaths | Unadjusted OR (95% CI) | Adjusted OR* (95% CI) | Adjusted OR† (95% CI) | |
|---|---|---|---|---|---|
| France | Ontario | ||||
| Any neonatal deaths‡ | 702 | 356 | 1.47 (0.95 to 2.29) | 1.59 (0.91 to 2.78) | 1.87 (1.04 to 3.35) |
| Neonatal deaths within 1 mo‡ | 638 | 344 | 1.36 (0.87 to 2.14) | 1.46 (0.82 to 2.58) | 1.76 (0.97 to 3.21) |
| Neonatal deaths within 5 mo‡ | 696 | 356 | 1.46 (0.94 to 2.27) | 1.57 (0.90 to 2.74) | 1.84 (1.03 to 3.29) |
| Neonatal deaths for births between 22 and 26 wk gestation | 502 | 266 | 2.06 (1.10 to 3.85) | 2.58 (1.13 to 5.89) | 2.81 (1.17 to 6.74) |
| Neonatal deaths within 1 mo | 470 | 259 | 1.90 (1.01 to 3.58) | 2.37 (1.03 to 5.44) | 2.57 (1.06 to 6.22) |
| Neonatal deaths within 5 mo | 497 | 267 | 2.02 (1.08 to 3.78) | 2.52 (1.10 to 5.75) | 2.71 (1.13 to 6.51) |
| Neonatal deaths for births between 27 and 31 wk gestation | 187 | 56 | 2.48 (0.86 to 7.13) | 1.98 (0.59 to 6.62) | 2.27 (0.66 to 7.73) |
| Neonatal deaths within 1 mo | 157 | 53 | 2.18 (0.73 to 6.49) | 1.78 (0.51 to 6.24) | 2.12 (0.59 to 7.59) |
| Neonatal deaths within 5 mo | 186 | 56 | 2.46 (0.85 to 7.09) | 1.97 (0.59 to 6.59) | 2.25 (0.66 to 7.67) |
| Neonatal deaths for births between 32 and 34 wk gestation | 13 | 34 | 1.58 (0.39 to 6.46) | 1.47 (0.34 to 6.46) | 1.27 (0.28 to 5.71) |
| Neonatal deaths within 1 mo | 11 | 32 | 1.37 (0.32 to 5.84) | 1.30 (0.28 to 5.95) | 1.20 (0.26 to 5.64) |
| Neonatal deaths within 5 mo | 13 | 33 | 1.58 (0.39 to 6.46) | 1.47 (0.34 to 6.46) | 1.27 (0.28 to 5.71) |
Note: CI = confidence interval, OR = odds ratio.
↵* Models adjusted for maternal age, gestational hypertension, assisted reproductive therapy, infant birth weight and multifetal pregnancy.
↵† Models additionally adjusted for cesarean delivery, antenatal steroid use and delivery in a hospital with level 3 care.
↵‡ Regression models weighted to account for stratified sampling methodology used by EPIPAGE-2 in setting up the cohort in France.